Carcinoma
Services
Online Inquiry

Carcinoma

Carcinoma is a cancer that begins in the cells that make up the lining tissue of the skin or organs, such as the liver or kidneys, while others begin in other types of tissue, such as blood cancer and bone cancer. Alfa Cytology is a world leader in the development of cancer vaccines. With our extensive experience and advanced platform, we can provide the best vaccine development services for carcinoma.

Introduction to Carcinoma

Like other types of cancer, carcinoma is abnormal cells that divide uncontrollably. They can spread to other parts of the body, but not always.

Current Status of Carcinoma Immunotherapy

With the focus on carcinoma immunotherapy and the widespread use of immune checkpoint inhibitors, strategies that highly seek to improve the response rate and duration of current carcinoma immunotherapy have become mainstream. Multiple platforms have been used for carcinoma vaccine development, from live viruses and bacterial preparations with antigens to synthetic peptides that promise to generate a robust and long-lasting immune response against carcinoma.

Studies have shown that carcinoma vaccines alone may trigger tumor-specific cellular or humoral responses in immunoassays and even cause cancer to regress or shrink in selected trials, especially when combined with other carcinoma therapies, which is critical to achieving and optimizing reliable target responses and survival benefits.

The Mechanism of Carcinoma Vaccine

Carcinoma vaccines can harness the entire immune system, which includes bioengineered receptors or ligands to produce antigen-specific responses. In addition, advances in molecular technology have ensured the use of transgenic techniques or proteins of interest to enhance the immune response and increase the chance of immune recognition.

Carcinoma vaccines can be classified by biologics or antigen sources, such as nucleic acids, peptides, recombinant proteins, microbial vectors, autologous or allogeneic whole tumor cells, manipulated antigen-presenting cells (APCs), and other artificial systems.

Carcinoma vaccines can be classified by biologics or antigen sources.Fig. 1 Diverse therapeutic carcinoma vaccine platforms. (Maeng, H. M., et al., 2019)

Our Service

Carcinoma is the most common form of cancer, accounting for 80 to 90 percent of cancer diagnoses. Traditional therapies include chemotherapy, radiation, and surgery. Now immunotherapy is showing powerful effects, especially with cancer vaccines. It is more useful in combination with other therapies. Therefore, Alfa Cytology provides diversified carcinoma vaccine development services, including but not limited to the following.

Carcinoma immunotherapy has established its status as the fourth pillar of anticancer therapy, and carcinoma vaccine research has made a lot of breakthroughs. Alfa Cytology is committed to solving various problems in the field of carcinoma vaccine development and has in-depth and extensive experience in preclinical services. If you are interested in our service, please contact us for more details.

Reference

  1. Maeng, H. M., & Berzofsky, J. A. (2019) Strategies for developing and optimizing cancer vaccines. F1000Res. 8: F1000 Faculty Rev-654.
 For Research Only.